Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
20.4 USD | +1.04% | +5.39% | -26.03% |
Apr. 15 | Goldman Sachs Cuts Veracyte Price Target to $28 From $32, Maintains Buy Rating | MT |
Feb. 26 | Morgan Stanley Trims Veracyte's Price Target to $21 From $22, Keeps Underweight Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.03% | 1.54B | |
-16.26% | 11.13B | |
+65.07% | 3.6B | |
-30.76% | 2.26B | |
-14.31% | 2.16B | |
+35.34% | 1.17B | |
-2.40% | 744M | |
-39.18% | 432M | |
+13.72% | 357M | |
+15.53% | 225M |
- Stock Market
- Equities
- VCYT Stock
- News Veracyte, Inc.
- Morgan Stanley Trims Price Target on Veracyte to $22 From $23, Maintains Underweight Rating